SV2001000570A - Agente terapeutico cristalino ref. pcs22011afae/bb - Google Patents

Agente terapeutico cristalino ref. pcs22011afae/bb

Info

Publication number
SV2001000570A
SV2001000570A SV2001000570A SV2001000570A SV2001000570A SV 2001000570 A SV2001000570 A SV 2001000570A SV 2001000570 A SV2001000570 A SV 2001000570A SV 2001000570 A SV2001000570 A SV 2001000570A SV 2001000570 A SV2001000570 A SV 2001000570A
Authority
SV
El Salvador
Prior art keywords
crystal
therapeutic agent
agent ref
ref
piridilsulfonil
Prior art date
Application number
SV2001000570A
Other languages
English (en)
Spanish (es)
Inventor
Laurence James Harris
Richard Anthony Storey
Wood Albert Shaw
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of SV2001000570A publication Critical patent/SV2001000570A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
SV2001000570A 2000-07-28 2001-07-27 Agente terapeutico cristalino ref. pcs22011afae/bb SV2001000570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
SV2001000570A true SV2001000570A (es) 2002-09-03

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000570A SV2001000570A (es) 2000-07-28 2001-07-27 Agente terapeutico cristalino ref. pcs22011afae/bb

Country Status (45)

Country Link
EP (1) EP1305314B1 (https=)
JP (1) JP2004505087A (https=)
KR (1) KR100457937B1 (https=)
CN (1) CN1207297C (https=)
AP (1) AP1400A (https=)
AR (1) AR032628A1 (https=)
AT (1) ATE286901T1 (https=)
AU (2) AU7269001A (https=)
BG (1) BG107266A (https=)
BR (1) BR0112734A (https=)
CA (1) CA2417264C (https=)
CZ (1) CZ2003126A3 (https=)
DE (1) DE60108398T2 (https=)
DO (1) DOP2001000217A (https=)
DZ (1) DZ3364A1 (https=)
EA (1) EA004681B1 (https=)
EC (1) ECSP034454A (https=)
EE (1) EE200300045A (https=)
ES (1) ES2231521T3 (https=)
GE (1) GEP20053494B (https=)
HR (1) HRP20030061A2 (https=)
HU (1) HUP0302982A3 (https=)
IL (1) IL153226A0 (https=)
IN (1) IN2002MU01649A (https=)
IS (1) IS6626A (https=)
MA (1) MA26931A1 (https=)
MX (1) MX233602B (https=)
MY (1) MY117831A (https=)
NO (1) NO324220B1 (https=)
NZ (1) NZ523226A (https=)
OA (1) OA12337A (https=)
PA (1) PA8523501A1 (https=)
PE (1) PE20020277A1 (https=)
PH (1) PH12001001922B1 (https=)
PL (1) PL365133A1 (https=)
PT (1) PT1305314E (https=)
SK (1) SK572003A3 (https=)
SV (1) SV2001000570A (https=)
TN (1) TNSN01112A1 (https=)
TW (1) TWI285643B (https=)
UA (1) UA72631C2 (https=)
UY (1) UY26854A1 (https=)
WO (1) WO2002010171A1 (https=)
YU (1) YU4703A (https=)
ZA (1) ZA200301457B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
BRPI0609225A2 (pt) * 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000712A2 (en) * 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
DE60108398T2 (de) 2005-12-22
CN1444585A (zh) 2003-09-24
MA26931A1 (fr) 2004-12-20
MXPA03000856A (es) 2003-06-06
PT1305314E (pt) 2005-04-29
UY26854A1 (es) 2002-02-28
ECSP034454A (es) 2003-03-10
CN1207297C (zh) 2005-06-22
CZ2003126A3 (cs) 2004-02-18
AU2001272690B2 (en) 2005-12-08
MY117831A (en) 2004-08-30
HUP0302982A3 (en) 2005-01-28
YU4703A (sh) 2006-01-16
HK1055954A1 (en) 2004-01-30
ATE286901T1 (de) 2005-01-15
ES2231521T3 (es) 2005-05-16
ZA200301457B (en) 2004-04-28
BG107266A (bg) 2003-07-31
NZ523226A (en) 2003-07-25
PH12001001922B1 (en) 2006-11-21
CA2417264A1 (en) 2002-02-07
EA004681B1 (ru) 2004-06-24
HRP20030061A2 (en) 2003-04-30
AP1400A (en) 2005-04-28
PA8523501A1 (es) 2002-10-24
WO2002010171A1 (en) 2002-02-07
BR0112734A (pt) 2004-08-10
HUP0302982A2 (hu) 2003-12-29
AR032628A1 (es) 2003-11-19
KR100457937B1 (ko) 2004-11-20
PL365133A1 (en) 2004-12-27
AP2001002234A0 (en) 2001-09-30
JP2004505087A (ja) 2004-02-19
IL153226A0 (en) 2003-07-06
DZ3364A1 (fr) 2002-02-07
SK572003A3 (en) 2004-05-04
EP1305314A1 (en) 2003-05-02
MX233602B (es) 2006-01-10
NO20030416L (no) 2003-02-05
EP1305314B1 (en) 2005-01-12
PE20020277A1 (es) 2002-05-11
OA12337A (en) 2006-05-15
UA72631C2 (uk) 2005-03-15
NO324220B1 (no) 2007-09-10
TWI285643B (en) 2007-08-21
EE200300045A (et) 2004-12-15
CA2417264C (en) 2007-06-12
DOP2001000217A (es) 2002-10-30
GEP20053494B (en) 2005-04-25
NO20030416D0 (no) 2003-01-27
KR20030016430A (ko) 2003-02-26
EA200300079A1 (ru) 2003-06-26
IS6626A (is) 2002-11-18
AU7269001A (en) 2002-02-13
TNSN01112A1 (fr) 2005-11-10
DE60108398D1 (de) 2005-02-17
IN2002MU01649A (https=) 2004-12-11

Similar Documents

Publication Publication Date Title
DE60112974D1 (en) Carbolinderivate
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
BRPI0010891B8 (pt) geração de microespuma terapêutica.
GB9514473D0 (en) Chemical compounds
AU2002221239A1 (en) Therapeutic benzimidazole compounds
AU2001252135A1 (en) Therapeutic agents
MXPA03000803A (es) Suministro vaginal de bisfosfonatos.
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
NO20021695D0 (no) 5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorer
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
EE9900539A (et) Uued ühendid
NO20021328D0 (no) Pyrazolopyrimidiner som terapeutiske midler
MXPA02012076A (es) Compuestos quimicos.
DE60216233D1 (en) Carbolinderivate
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
IS6980A (is) 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum
MXPA02012472A (es) Compuestos quimicos.
SV2001000570A (es) Agente terapeutico cristalino ref. pcs22011afae/bb
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
AU2002331972A1 (en) 3,4-methylenedioxy-substituted chalcones as therapeutic agents
IS6990A (is) 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum

Legal Events

Date Code Title Description
FD Lapse